Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GSK3B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GSK3B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GSK3B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GSK3B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GSK3B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00108213 | Colorectum | FAP | regulation of mitochondrion organization | 35/2622 | 144/18723 | 6.44e-04 | 7.05e-03 | 35 |
GO:0010675 | Colorectum | FAP | regulation of cellular carbohydrate metabolic process | 35/2622 | 146/18723 | 8.41e-04 | 8.72e-03 | 35 |
GO:00182102 | Colorectum | FAP | peptidyl-threonine modification | 31/2622 | 125/18723 | 8.93e-04 | 9.08e-03 | 31 |
GO:19012153 | Colorectum | FAP | negative regulation of neuron death | 46/2622 | 208/18723 | 9.52e-04 | 9.42e-03 | 46 |
GO:00353044 | Colorectum | FAP | regulation of protein dephosphorylation | 24/2622 | 90/18723 | 1.12e-03 | 1.08e-02 | 24 |
GO:00181072 | Colorectum | FAP | peptidyl-threonine phosphorylation | 29/2622 | 116/18723 | 1.12e-03 | 1.08e-02 | 29 |
GO:00190822 | Colorectum | FAP | viral protein processing | 11/2622 | 29/18723 | 1.20e-03 | 1.14e-02 | 11 |
GO:19030524 | Colorectum | FAP | positive regulation of proteolysis involved in cellular protein catabolic process | 32/2622 | 133/18723 | 1.28e-03 | 1.19e-02 | 32 |
GO:0001837 | Colorectum | FAP | epithelial to mesenchymal transition | 36/2622 | 157/18723 | 1.67e-03 | 1.47e-02 | 36 |
GO:0021987 | Colorectum | FAP | cerebral cortex development | 28/2622 | 114/18723 | 1.80e-03 | 1.55e-02 | 28 |
GO:0060485 | Colorectum | FAP | mesenchyme development | 59/2622 | 291/18723 | 1.94e-03 | 1.64e-02 | 59 |
GO:00301781 | Colorectum | FAP | negative regulation of Wnt signaling pathway | 38/2622 | 170/18723 | 2.06e-03 | 1.70e-02 | 38 |
GO:00726981 | Colorectum | FAP | protein localization to microtubule cytoskeleton | 16/2622 | 54/18723 | 2.26e-03 | 1.84e-02 | 16 |
GO:00109214 | Colorectum | FAP | regulation of phosphatase activity | 22/2622 | 84/18723 | 2.27e-03 | 1.84e-02 | 22 |
GO:0008286 | Colorectum | FAP | insulin receptor signaling pathway | 28/2622 | 116/18723 | 2.37e-03 | 1.89e-02 | 28 |
GO:0048016 | Colorectum | FAP | inositol phosphate-mediated signaling | 16/2622 | 55/18723 | 2.78e-03 | 2.15e-02 | 16 |
GO:0010721 | Colorectum | FAP | negative regulation of cell development | 39/2622 | 180/18723 | 3.25e-03 | 2.40e-02 | 39 |
GO:00105081 | Colorectum | FAP | positive regulation of autophagy | 29/2622 | 124/18723 | 3.30e-03 | 2.43e-02 | 29 |
GO:19012162 | Colorectum | FAP | positive regulation of neuron death | 24/2622 | 97/18723 | 3.33e-03 | 2.44e-02 | 24 |
GO:00507731 | Colorectum | FAP | regulation of dendrite development | 25/2622 | 103/18723 | 3.64e-03 | 2.60e-02 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3B | SNV | Missense_Mutation | | c.46N>T | p.Pro16Ser | p.P16S | P49841 | protein_coding | tolerated_low_confidence(0.36) | benign(0.003) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | novel | c.857C>G | p.Pro286Arg | p.P286R | P49841 | protein_coding | deleterious(0.03) | benign(0.162) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
GSK3B | insertion | Nonsense_Mutation | novel | c.1146_1147insGAAACCGGGAGGCGGAGGTTGCATTGAGCCGAGATTGCGCC | p.Asn383GlufsTer9 | p.N383Efs*9 | P49841 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
GSK3B | insertion | In_Frame_Ins | novel | c.44_45insATCACAAGGAGAACTCTGTTTTGA | p.Lys15_Pro16insSerGlnGlyGluLeuCysPheGlu | p.K15_P16insSQGELCFE | P49841 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GSK3B | deletion | Frame_Shift_Del | novel | c.850delN | p.Met284Ter | p.M284* | P49841 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
GSK3B | SNV | Missense_Mutation | novel | c.259G>A | p.Val87Ile | p.V87I | P49841 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | novel | c.683N>A | p.Ile228Asn | p.I228N | P49841 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3B | SNV | Missense_Mutation | rs72548709 | c.995N>A | p.Arg332His | p.R332H | P49841 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSK3B | SNV | Missense_Mutation | | c.713N>C | p.Ile238Thr | p.I238T | P49841 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GSK3B | SNV | Missense_Mutation | | c.901T>C | p.Trp301Arg | p.W301R | P49841 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | PMID26161698-Compound-18 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | Neu-120 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | SOTRASTAURIN | SOTRASTAURIN | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | CYC-116 | CYC-116 | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | tideglusib | TIDEGLUSIB | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | 404859135 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | ALSTERPAULLONE | ALSTERPAULLONE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL1200826 | LITHIUM CARBONATE | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | AMO-02 | | |
2932 | GSK3B | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | BETULINIC ACID | BETULINIC ACID | 19716700 |